Published in Menopause on June 06, 2003
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens (2003) 1.49
Non-genomic actions of sex steroid hormones. Eur J Endocrinol (2003) 1.48
Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause (2007) 1.47
Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) (2009) 1.44
Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol (2006) 1.35
IMS updated recommendations on postmenopausal hormone therapy. Climacteric (2007) 1.20
Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation (2002) 1.11
Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod (2007) 1.08
Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol (2008) 1.08
Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One (2008) 1.08
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J (2007) 1.07
Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecol Endocrinol (2013) 1.02
Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids (2002) 0.98
EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas (2010) 0.97
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer (2010) 0.97
Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology (2003) 0.97
Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology (2004) 0.96
Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab (2008) 0.95
Compensatory feto-placental upregulation of the nitric oxide system during fetal growth restriction. PLoS One (2012) 0.95
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril (2008) 0.95
Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol (2006) 0.93
EMAS position statement: Vitamin D and postmenopausal health. Maturitas (2011) 0.92
Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod (2008) 0.90
Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. J Assist Reprod Genet (2008) 0.88
Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas (2003) 0.87
P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res (2006) 0.87
Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol (2009) 0.86
Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol (2010) 0.86
EMAS position statement: Managing women with premature ovarian failure. Maturitas (2010) 0.86
EMAS position statement: managing obese postmenopausal women. Maturitas (2010) 0.85
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril (2010) 0.84
EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas (2011) 0.84
Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology (2002) 0.84
Pregnancy complications in polycystic ovary syndrome patients. Gynecol Endocrinol (2014) 0.83
Self-reported sexual symptoms in women attending menopause clinics. Gynecol Obstet Invest (2002) 0.83
Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril (2003) 0.83
Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging (2007) 0.83
Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas (2006) 0.82
Sex steroids and breast cancer metastasis. Horm Mol Biol Clin Investig (2010) 0.82
Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol (2002) 0.81
Effects of oral contraceptives on bone mineral density. Treat Endocrinol (2004) 0.81
Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas (2005) 0.81
Circulating levels of neuroactive steroids in patients with binge eating disorder: a comparison with nonobese healthy controls and non-binge eating obese subjects. Int J Eat Disord (2003) 0.80
Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause (2005) 0.80
Membrane integrity evaluation in rabbit spermatozoa. Eur J Obstet Gynecol Reprod Biol (2002) 0.80
Serum allopregnanolone levels relate to FSFI score during the menstrual cycle. J Sex Marital Ther (2003) 0.80
The metabolic syndrome and its components in postmenopausal women. Gynecol Endocrinol (2013) 0.80
Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol (2006) 0.80
Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause (2008) 0.80
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas (2007) 0.79
Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas (2005) 0.79
Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and beta-endorphin. Maturitas (2002) 0.79
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas (2002) 0.79
Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome. Maturitas (2012) 0.79
Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. J Matern Fetal Neonatal Med (2012) 0.79
Estrogen-like effects of wine extracts on nitric oxide synthesis in human endothelial cells. Maturitas (2011) 0.79
Hormonal influence on the central nervous system. Maturitas (2002) 0.79
Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception (2007) 0.78
EMAS position statement: managing the menopause in women with epilepsy. Maturitas (2010) 0.78
Skeletal status and body composition in young women with functional hypothalamic amenorrhea. Gynecol Endocrinol (2011) 0.78
Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause (2010) 0.78
Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. Gynecol Endocrinol (2007) 0.78
Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril (2006) 0.78
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]. Kardiol Pol (2007) 0.77
Pharmacotherapy: Benefits of menopausal hormone therapy--timing is key. Nat Rev Endocrinol (2012) 0.77
Differential estrogen signaling in endothelial cells upon pulsed or continuous administration. Maturitas (2005) 0.77
EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas (2010) 0.77
EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas (2010) 0.77
Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab (2004) 0.77
A randomized control comparison study of culture media (HTF versus P1) for human in vitro fertilization. Eur J Obstet Gynecol Reprod Biol (2004) 0.77
The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. Gynecol Endocrinol (2007) 0.77
Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol (2010) 0.76
Clinical relevance of the HERS trial. Lancet (2002) 0.76
Clinical evaluation of patients with weight loss-related amenorrhea: neuropeptide Y and luteinizing hormone pulsatility. Gynecol Endocrinol (2006) 0.76
[Cardiovascular effects of selective estrogen receptor modulators. Current perspectives]. Recenti Prog Med (2003) 0.76
One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas (2008) 0.76
Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas (2002) 0.76
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas (2011) 0.75
Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol (2012) 0.75
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecol Endocrinol (2007) 0.75
Dehydroepiandrosterone, the endothelium, and cardiovascular protection. Endocrinology (2007) 0.75
Hard stuff for the bones. Menopause (2012) 0.75
When hormone therapy sneaks under your nose. Menopause (2008) 0.75
Vasomotor symptoms and negative affect: time to act. Menopause (2011) 0.75
Menopausal hot flashes: still an undiscovered territory. Menopause (2009) 0.75
From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. Gynecol Endocrinol (2006) 0.75
Estrogen regulates endothelial migration via plasminogen activator inhibitor (PAI-1). Mol Hum Reprod (2012) 0.75
The fetal brain: role of progesterone and allopregnanolone. Horm Mol Biol Clin Investig (2016) 0.75
European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol (2015) 0.75
Estrogens and women's health: a scary or a fairy tale? Gynecol Endocrinol (2004) 0.75
The Xmas present for women's health: a strike to osteoporosis prevention. Maturitas (2004) 0.75
ISGE statement on oral emergency contraception. Gynecol Endocrinol (2014) 0.75
Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Mol Hum Reprod (2011) 0.75
Does nuchal translucency thickness in the first trimester predict GDM onset during pregnancy? Gynecol Endocrinol (2010) 0.75
The osteoporosis dilemma. Gynecol Endocrinol (2004) 0.75